CG Oncology, Inc. reports results for the quarter ended June 30 - Earnings Summary
CG Oncology, Inc. reports results for the quarter ended June 30 - Earnings Summary
CG Oncology, Inc. CGON.OQ reported a quarterly adjusted loss of 90 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -54 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 66 cents per share. Wall Street expected results to range from -73 cents to -52 cents per share.
Revenue was $1.16 million; analysts expected $360.42 thousand.
CG Oncology, Inc.'s reported EPS for the quarter was a loss of 90 cents.
The company reported a quarterly loss of $79.06 million.
CG Oncology, Inc. shares had risen by 1.9% this quarter and gained 74.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 10.4% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for CG Oncology, Inc. is $88.50, about 18.2% above its last closing price of $72.42
This summary was machine generated from LSEG data August 6 at 02:21 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.66 | -0.90 | Missed |
Mar. 31 2026 | -0.58 | -0.71 | Missed |
Dec. 31 2025 | -0.61 | -0.53 | Beat |
Sep. 30 2025 | -0.56 | -0.57 | Missed |